Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma

Note: Funding Information: KS, RS, AH, NvE, CMZ, AB and JvdL received institutional funding from Pfizer. FK, HT, AR, JF, JLP and WW have no conflicts of interest to declare. Funding Information: Pfizer Inc. provided funding and a clinical research collaboration to implement the CRISP trial. The CRISP trial was sponsored by Erasmus MC Sophia Children’s Hospital, Department of Pediatrics, Rotterdam, The Netherlands, and was funded by the Erasmus MC Vriendenfonds Funding Information: Pfizer Inc. provided funding and a clinical research collaboration to implement the CRISP trial. The CRISP trial was sponsored by Erasmus MC Sophia Children’s Hospital, Department of Pediatrics, Rotterdam, The Netherlands, and was funded by the Erasmus MC Vriendenfonds (now Erasmus MC Foundation), Pfizer and Go4Children to CMZ. The NHL-BFM Registry 2012 was supported by grants from the Deutsche Kinderkrebsstiftung to WW (DKS 2014.11, 2016.24, 2018.21, 2020.15).